Collegium Pharmaceutical, Inc. Net Income 2013–2025
Collegium Pharmaceutical, Inc. reported $62.87M of net income for fiscal 2025. That was 9.1% lower than fiscal 2024. Compared with fiscal 2020, the change was +135.0%.
| Fiscal year | Net Income | Net margin | Change (YoY) |
|---|---|---|---|
| FY 2025 | $62.87M | 8.1% | -9.1% |
| FY 2024 | $69.19M | 11.0% | +43.7% |
| FY 2023 | $48.16M | 8.5% | +292.6% |
| FY 2022 | $-25.00M | -5.4% | -135.0% |
| FY 2021 | $71.52M | 25.8% | +167.3% |
| FY 2020 | $26.75M | 8.6% | +217.7% |
| FY 2019 | $-22.72M | -7.7% | +41.9% |
| FY 2018 | $-39.13M | -14.0% | +47.7% |
| FY 2017 | $-74.86M | -262.9% | +20.5% |
| FY 2016 | $-94.18M | -5504.1% | -245.5% |
| FY 2015 | $-27.25M | — | -52.1% |
| FY 2014 | $-17.92M | — | -10.6% |
| FY 2013 | $-16.20M | — | — |
Source: Collegium Pharmaceutical, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open COLL 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Collegium Pharmaceutical, Inc. reported $62.87M of net income for fiscal 2025. That was 9.1% lower than fiscal 2024. Compared with fiscal 2020, the change was +135.0%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Collegium Pharmaceutical, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeCollegium Pharmaceutical, Inc. — frequently asked questions
What is Collegium Pharmaceutical, Inc.'s net income?
Collegium Pharmaceutical, Inc. (COLL) reported net income of $62.87M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Collegium Pharmaceutical, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.